Generic placeholder image

Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)


ISSN (Print): 1871-5222
ISSN (Online): 1875-6115

Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus

Author(s): Anishkumar Chaurasia, Rashmi Mallya and Tabassum Khan

Volume 16, Issue 1, 2016

Page: [18 - 30] Pages: 13

DOI: 10.2174/1871522216666160216225721

Price: $65


A number of conventional therapeutic targets are available for treatment of Type 2 diabetes mellitus (T2DM) but due to development of resistance by using conventional drug as monotherapy, there is a need to identify novel therapeutic targets and/or use combination of conventional and novel drugs for diabetes therapy. In this review we have highlighted some of the novel approaches like inhibitors of (11- Hydroxysteroid dehydrogenase type-1, Sodium-glucose linked cotransporter-2, Acyl-CoA Diacylglycerol Acyl Transferase-1, Glycogen phosphorylase-A, Pyruvate Dehydrogenase Kinase, Protein tyrosine phosphate 1B, Kappa kinase-B, Stearoyl-coA desaturase-1), antagonists of (Fatty acid binding proteins, Fibroblast growth factors-21 receptor, Glucagon receptor, Glucocorticoid receptors), Glucokinase and Sirtuin activators, Cannabinoid receptor blockers, Incretin-mimetics, agonists of (Adenosine monophosphate activated protein kinase, Augmenting GLP-1 secretion GPR40, GPR120, GPR 146 and TGR 5, GPCR 119, liver x receptors, Serotonin 2c receptor) and Rexinoids x receptor modulators developed for the treatment of diabetes.

Keywords: 11-Hydroxysteroid dehydrogenase type 1 inhibitors, glucagon receptor antagonist, glucokinase activators, incretin mimetics, liver x receptors, type-2 Diabetes Mellitus.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy